Latest From Athersys Inc.
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- BTHC VI Inc.
- North America
- Parent & Subsidiaries
- Athersys Inc.
- Senior Management
Gil Van Bokkelen, PhD, Chmn. & CEO
Ivor Macleod, CFO
John Harrington, PhD, EVP, CSO
William Lehmann, JD, President & COO
- Contact Info
Phone: (216) 431-9900
3201 Carnegie Ave.
Cleveland, OH 44115-2634
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.